High risk infants and young children eligible for palivizumab
Association between rates of RSV hospitalization and site of palivizumab administration
17,641 in clinic setting and 1226 in home setting
88% in home setting and 81% in clinic setting received the appropriate number of dosing
Received palivizumab at home: 0.4% (5/1226) Received palivizumab in clinic: 1.2% (207/17,641) ()
Home administration of palivizumab may be preferred for high risk infants at risk of RSV hospitalization
Low
(18) Palivizumab Outcomes Registry Study Group, 2003, USA [34]
Record review
2000-2001
All children eligible for palivizumab according to AAP guidelines [40]
Received at least one dose of palivizumab
2,049
1,638 of 2,049 (80%) children were compliant with the scheduled dosing of palivizumab 472 (23%) of 2,049 infants missed or had a delay in receiving an injection
RSV hospitalization slightly higher in noncompliant infants (3.4% versus 2.8%, ) Hospitalization rate significantly higher in infants who missed or delayed an injection (4.4% versus 2.4%) ()
Missed or delayed palivizumab injections may increase the incidence of hospitalization
Relation between different dosing rate of palivizumab and hospital admission
1965 infants
0 doses: <29 week GA = 42%, 29–31 week GA = 39.8% At least 1 dose: <29 week GA = 58%, 29–31 week GA = 60.2% Full dose: <29 week GA = 14.8%, 29–31 week GA = 17.6%
Weak positive correlation between palivizumab dosing and hospital admissions
Spearman rho = 0.012
Overall reduced dosing of palivizumab and seasonal variation in severity of RSV disease may have affected the results